Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).
Miriam Koopman
Consultant or Advisory Role - Amgen; Bayer; Merck Serono; Roche/Genentech; Sanofi
Lieke Simkens
No relevant relationships to disclose
Anne Maria May
No relevant relationships to disclose
Linda Mol
No relevant relationships to disclose
Harm van Tinteren
No relevant relationships to disclose
Cornelis J. A. Punt
Consultant or Advisory Role - Amgen; Bayer; Merck Serono; Roche/Genentech; Sanofi